Gleevec's latest approval is for pediatric cancer

(HealthDay)—The anti-cancer drug Gleevec (imatinib) has received new U.S. Food and Drug Administration approval to treat the most common type of pediatric cancer, affecting some 2,900 children each year, the agency said Friday.

Philadelphia chromosome positive (ALL) progresses rapidly if left untreated. Gleevec, among a class of drugs called , blocks proteins that promote development of cancer cells, the FDA said in a news release.

The most common side effects observed in pediatric testing included infection and a decrease in white blood cells and blood platelets.

Gleevec was first approved in 2001 to treat a form of , and has since been approved to treat several other conditions. The drug is marketed by Novartis, based in East Hanover, N.J.

More information: To learn more about Gleevec, visit the U.S. National Cancer Institute.

Related Stories

Iclusig approved for rare leukemias

date Dec 16, 2012

(HealthDay)—Iclusig (ponatinib) has been approved by the U.S. Food and Drug Administration to treat two rare forms of leukemia..

Marqibo approved for ph- acute lymphoblastic leukemia

date Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with Philadelphia chromosome negative acute lymphoblastic leukemia ...

Marqibo approved for rare leukemia

date Aug 10, 2012

(HealthDay) -- Marqibo (vincristine sulfate liposome injection) has been approved by the U.S. Food and Drug Administration to treat adults with a rare form of blood and bone marrow cancer, Philadelphia chromosome negative ...

Synribo approved to treat rare leukemia

date Oct 26, 2012

(HealthDay)—Synribo (omacetaxine mepesuccinate) has been approved by the U.S. Food and Drug Administration to treat a rare blood and bone marrow disease called chronic myelogenous leukemia (CML).

Recommended for you

Self-reported health predicts survival in breast cancer

date 16 hours ago

(HealthDay)—For older women with breast cancer, low self-rated health (SRH) and limited walking ability predict worse all-cause survival at five and 10 years, according to a study published in the April ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.